Does HOWL pay a dividend and is it safe?

Werewolf Therapeutics Inc. (HOWL) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / HOWL / dividends

ANVS (35) SER (31) GANX (41) ATNM (43) ⌘ Pro Terminal →

Werewolf Therapeutics Inc. (HOWL) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.05 +6.48% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.06

Werewolf Therapeutics Inc. (HOWL) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $47.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on HOWL Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is HOWL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Werewolf Therapeutics Inc. (NASDAQ: HOWL) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $1.05 (+6.48% 1D, market cap $47.9M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, HOWL ranks #428 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does HOWL compare to ANVS and SER in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HOWL carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ANVS (Annovis Bio Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $48.2M) and SER (Serina Therapeutics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $49.3M). Among the 5-stock peer group, HOWL leads on earnings multiple (N/A) while HOWL leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for HOWL?

▼

Per HOWL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001785530), Werewolf Therapeutics Inc. generated $169.9M in revenue (-17.6% YoY), -$60.8M in net income, and -$60.3M in free cash flow against $69.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.06 (+0.98%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 Quant Analysts Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-7.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HOWL)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (42/100 Composite)

🔍 WHY HOWL SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+12/20 pts (29% of score)

FRED Regime × Technicals: 74% of 52W Range • RSI-14 at 51.2 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+11/20 pts (26% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$0.98+6.1% Next Q

Q2 (-2Q)

Grade E$1.04-5.8% Next Q

Q3 (-1Q)

Grade E$0.98+7.1% Next Q

Current

Grade D-$1.05-7% Hist 90D α

Trajectory: E (34) → D- (42)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a HOWL Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While HOWL currently carries a cautious 42/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.97) and Max Pain ($1.10) forces dealer call-delta covering toward $1.40.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HOWL• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “HOWL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 42%NO 58%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HOWL)

✓Walkthrough of HOWL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

HOWL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +52.17%⚡ TESTING RESISTANCE

2026-11-03O $1.10H $1.10L $0.99C $1.05VOL 415.6K

RES: $1.10SUP: $0.53SMA50: $0.97SMA200: $0.68

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HOWL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HOWL Butterfly Map → + Track HOWL →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -17.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on HOWL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HOWL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for HOWL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HOWL)

Health Care Rank #428 of 1015 ⚔️ ANVS vs HOWL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HOWL vs. ANVS, SER, GANX, ATNM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Werewolf Therapeutics Inc. (HOWL) ranks #428 by composite RQD confidence (42/100, grade D-) and #752 by equity capitalization ($47.9M). Within this direct 5-issuer industry benchmark cohort, HOWL leads on earnings valuation at N/A trailing P/E, while HOWL leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ATNM currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with HOWL at 42/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
HOWL ACTIVE Werewolf Therapeutics Inc.	D-	42/100	—	—	-35.0%	+6.48%	$47.9M	Benchmark Subject
ANVS Annovis Bio Inc.	D-	35/100	—	—	-35.0%	-4.42%	$48.2M	/anvs-vs-howl →
SER Serina Therapeutics Inc.	E	31/100	—	—	-35.0%	-4.64%	$49.3M	/ser-vs-howl →
GANX Gain Therapeutics Inc.	D-	41/100	—	—	-35.0%	0.00%	$49.3M	/ganx-vs-howl →
ATNM Actinium Pharmaceuticals Inc. (Delaware)	D-	43/100	—	—	-35.0%	-3.38%	$46.5M	/atnm-vs-howl →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001785530 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Werewolf Therapeutics Inc. (HOWL) reported GAAP revenue of $169.9M (-17.6% vs. FY2024 revenue of $206.1M , and +49.8% cumulative change since FY2023) , GAAP net income of -$60.8M, operating cash flow of -$60.3M, and free cash flow of -$60.3M (-6.8% YoY). On the balance sheet, HOWL closed FY2025 with $69.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$169.9M	-$60.8M	-$60.3M	-$60.3M	$69.4M	—
FY2024 (FY)	2024-12-31	$206.1M	-$70.5M	-$56.2M	-$56.4M	$126.9M	—
FY2023 (FY)	2023-12-31	$113.4M	-$37.4M	-$32.6M	-$32.6M	—	—

3. HOWL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HOWL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does HOWL compare to ANVS and SER in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for HOWL?

Where is HOWL trading relative to its 50-day, 200-day, and 52-week technical levels?

HOWL last traded at $1.05 (+6.48% on volume of 272,211 shares), positioning the stock +8.25% above its 50-day simple moving average ($0.97) and +54.41% above its 200-day simple moving average ($0.68). Across its 52-week range of $0.27 to $1.33, HOWL sits at the 73.6% percentile with a 14-day RSI of 51.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.18).

Direct Sub-Reports: HOWL RQD Cockpit HOWL 12M Forecast HOWL Earnings & Move HOWL Dividends & DRIP HOWL Insiders & 13F HOWL Whale Options HOWL Profit Sankey HOWL News & Why

ROARABLE RATING BRIEF • RQD 42/100 (D-) ✓ SEC XBRL & RQD VERIFIED

HOWL — Werewolf Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Werewolf Therapeutics Inc. (HOWL) earns a live Roarable RQD composite score of 42/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $1.05 (+6.48% 1D, market capitalization $47.9M).

Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
Whale 13F & Options Flow (11/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (12/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Werewolf Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The company's reported revenue is — in each of the listed periods, so its revenue model is not evident from the financials provided.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Werewolf Therapeutics Inc. (HOWL) reported $169.9M in annual revenue (up from $206.1M in FY2024, -17.6% YoY) and -$60.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($113.4M revenue, -$37.4M net income) through FY2025, HOWL scaled operating cash flow to -$60.3M and free cash flow to -$60.3M, backed by $69.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 42/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 11/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $0.27 – $1.33 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), HOWL carries a macro regime beta of 1.00 and gross margin of —.

Key Question #1: Can HOWL sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $169.9M and free cash flow of -$60.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is HOWL's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

HOWL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Werewolf Therapeutics Inc. (HOWL) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to HOWL Debate Forum (3) ↓

🟢 CATALYST Yahoo Finance • 1d ago

Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why

Yahoo Finance report covering Werewolf Therapeutics Inc. (HOWL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

HOWL Q3'26 Earnings: revenue estimate is 0 USD

TradingView report covering Werewolf Therapeutics Inc. (HOWL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Two cancer research posters accompany a Werewolf study selected for a Phoenix talk

Stock Titan report covering Werewolf Therapeutics Inc. (HOWL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting

Yahoo Finance report covering Werewolf Therapeutics Inc. (HOWL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Spotlight On 3 Penny Stocks With Market Caps As Low As $20M

Simply Wall St report covering Werewolf Therapeutics Inc. (HOWL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

TGTX Stock Rises 60% in 6 Months: Here's What You Should Know

TradingView report covering Werewolf Therapeutics Inc. (HOWL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Syfe • 1d ago

RNAZ Stock Price, Quote & News

Syfe report covering Werewolf Therapeutics Inc. (HOWL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 2d ago

New Strong Buy Stocks for October 9th

Yahoo Finance report covering Werewolf Therapeutics Inc. (HOWL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

HOWL Bull vs. Bear Conversation Board — What's Your Call at $1.05?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HOWL 🐻 33% BEARISH CONVICTION

QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $1.19 (+20.2%)

📌 Pinned Debate

A GREEN-flagged upgrade headline to Strong Buy and a 2.5 Altman Z-Score point to institutional interest and a balance sheet that has no

Long HOWL at $0.99 targeting $1.19. A GREEN-flagged upgrade headline to Strong Buy and a 2.5 Altman Z-Score point to institutional interest and a balance sheet that has not yet deteriorated to distress levels.. Institutional whale score is 11/20 and the risk/reward vs. the $0.27 52-week low is skewed heavily in favor of bulls.

ArenaChamp_24 🐂 BULL

@CreditSpread_Watch Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $0.84 (-15.2%)

Spot @ $0.99

With zero reported revenue, a -35% ROIC, a 0% FCF yield, and cash falling from $111.0M to $57.0M, the company is consuming capital with

Sitting on the sidelines or leaning short HOWL above $0.99. With zero reported revenue, a -35% ROIC, a 0% FCF yield, and cash falling from $111.0M to $57.0M, the company is consuming capital without a visible path to cash generation.. Until Fundamental Cash Engine (4/20) and FCF yield (0.0%) inflect higher, upside is capped near $1.43.